Full Press Release Details
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis.
BIIB
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
Key Takeaway: New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis